2026-HAMBURG
Join us for the 33rd ESGCT Annual Congress, which takes place in collaboration with DG-GT from 27-30 October 2026 at the Congress Center Hamburg, Germany.
top of page
COMMUNICATION
SCIENTIFIC EXCELLENCE EDUCATION
NETWORKING
We promote basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
IN MEMORY OF Professor Claudio Bordignon
We are greatly saddened by the loss of Professor Claudio Bordignon, a pioneer in the field, and the first ESGCT President
Outstanding Achievement Award
In 2025, the ESGCT Board and scientific committees were delighted to present the Outstanding Achievement Award to Juan Bueren
OUR EVENTS
LATEST NEWS
AMM-Only Project Pioneers Grant Programme 2026: Funding Innovative Research in Duchenne Muscular Dystrophy - Applications Now Open
AMM-Only Project, a Monaco-based association dedicated to advancing research in Duchenne muscular dystrophy (DMD) and related neuromuscular diseases, is pleased to announce the opening of applications for the 2026 edition of the Pioneers Grant Programme. Launched in 2025, the Pioneers Grant Programme was created to accelerate scientific discovery and the development of innovative therapeutic approaches for Duchenne muscular dystrophy and other neuromuscular disorders. The pro
Genome Engineering : Research and Applications
July 6–9, 2026 | Porto, Portugal | Sheraton Porto Hotel & Spa KEYNOTE SPEAKER Luigi Naldini, MD, PhD
MOOC on gene and gene-based cell therapies for rare diseases
Foundation For Rare Diseases (Fondation Maladies Rares, France) organises an online MOOC on gene and gene-based cell therapies for rare diseases . The course features contributions from leading U.S. and European researchers — including Alain Fischer, Heather Gray Edwards, Alessio Cantore, Zoltan Ivics, Sylvie Odent, Salima Hacein-Bey-Abina, Manuel Gonçalves, Marina Cavazzana, Allison Bradbury, Anne Galy, Chantal Pichon, Claire Booth, Jeffrey Medin , among others — as well a
In memory of Professor Claudio Bordignon
ESGCT are greatly saddened by the loss of Professor Claudio Bordignon, a pioneer in the gene therapy field, and the first President of the ESGCT.
FDA approval of LAD gene therapy
Last Thursday, the FDA approved the LAD gene therapy developed by Juan A. Bueren and Elena Almarza, in collaboration with the Adrian Thrasher team. This treatment was licensed to Rocket Pharma, who developed the clinical trial and presented it to the FDA. We believe this is terrific news for the gene therapy field and for ESGCT, as all these advances have come from ESGCT members, and the society has played a fundamental role in favouring this collaboration and in the developm
ForTra gGmbH and the SPARK-BIH team cordially invite you to their joint workshop on GCT in Frankfurt/Main
The ForTra gGmbH (the nonprofit subsidiary of the Else Kröner-Fresenius Foundation for research transfer) and the SPARK-BIH team of the National Strategy for Gene- and Cell-Based Therapies cordially invite you to their joint workshop on GCT in Frankfurt/Main. Join ForTra and the SPARK-BIH team of the National Strategy for Gene- and Cell-Based Therapies for an inspiring, forward-looking workshop on Gene and Cell therapy (GCT) – one of the most dynamic fields shaping t
Around the World: Global Seminar Series Australasia - Thursday 26 February 2026
Hosted as part of the AROUND THE WORLD SERIES in collaboration with the Coalition of International Gene Therapy Societies.
FDA approval of the Biologics License Application (BLA) for Waskyra, the first gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).
The ESGCT would like to congratulate Fondazione Telethon and HSR-TIGET on the milestone achievement of the FDA approval of WAS ex vivo gene therapy. Please see below their statement: We are honoured to share a moment of profound significance for us, for patients, families, and the scientific community. The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra , the first gene therapy for the treatment of Wiskott-Aldrich
2025-SEVILLE
The 32nd ESGCT Annual Congress took place in collaboration with SETGYC from 7-10 October 2025 at Fibes in Seville. Congress delegates can log in to their online registration portal to access the Congress abstract book, online programme, and Certificate of Attendance. Login here > Abstracts published by Human Gene Therapy will be available soon. Event Statistics (Click to enlarge) We are very grateful for the support of all our sponsors and partners.
Around the World: Oncology, Hematology, and Cancer-Focused Cell and Gene Therapy in India
Hosted as part of the AROUND THE WORLD SERIES in collaboration with the Coalition of International Gene Therapy Societies.
jobs & COURSES
MSCA COFUND Postodoc Program BEYOND on Advanced Therapies
✨ We are pleased to share this exciting opportunity for postdoctoral researchers in advanced therapies. Applications are now open for BEYOND, a Marie Skłodowska-Curie Actions COFUND Postdoctoral Program in Advanced Therapies, co-funded by the European Union. BEYOND will recruit 35 postdoctoral fellows for fully funded 3-year fellowships at leading European research centres:• San Raffaele Telethon Institute for Gene Therpay - SR-Tiget (Italy)• Telethon Institute of Genetic
Help shape the future of gene & cell therapy policy in Europe
The European Society of Gene & Cell Therapy (ESGCT) is looking for a Public Affairs & Health Policy Lead to establish and drive its European policy and advocacy function. This is a unique opportunity for an experienced public affairs professional to: ✅ Shape policy on advanced therapies across Europe ✅ Engage with EU institutions, regulators and key stakeholders ✅ Develop evidence-based policy positions ✅ Work alongside leading scientists, clinicians and patient communities �
GCure – University of Coimbra is recruiting a Group Leader in Gene Therapy
The University of Coimbra (Portugal) is recruiting a Group Leader / Principal Investigator to join GCure, an ERA Chair project funded by Horizon Europe (GA 101186929), focused on strengthening Europe’s capacity in advanced gene therapy development. The position targets an internationally competitive researcher ready to build an independent research programme in areas such as: Viral vector engineering (AAV, lentiviral vectors) Scalable manufacturing and bioprocessing Quality c
GeneT – University of Coimbra recruits three Group Leaders in Gene Therapy
The University of Coimbra (Portugal) is recruiting three Group Leaders to join GeneT – The Gene Therapy Center of Excellence Portugal, a Horizon Europe Teaming for Excellence initiative. The positions target internationally competitive researchers ready to establish independent research programmes in one of the following areas: Cardiovascular & pulmonary genetic disorders Ear & ophthalmic disorders Metabolic/hepatic diseases Immunodeficiencies Haematological disorders Musculo
Lund University hires Assistant Professors in Immuno-oncology and Immunotherapy
Lund University, Sweden are recruiting three tenure-track Assistant Professors in Immuno-Oncology and Immunotherapy. Assistant professor in Immuno-Oncology and Immune Cell Engineering Assistant professor in Immunotechnology Assistant professor in Experimental Cancer Immunotherapy We are looking for candidates ready to build an internationally competitive research programme at the interface of immune engineering, mechanistic discovery, and clinical translation. The positions a
ForTra gGmbH and the SPARK-BIH team cordially invite you to their joint workshop on GCT in Frankfurt/Main
The ForTra gGmbH (the nonprofit subsidiary of the Else Kröner-Fresenius Foundation for research transfer) and the SPARK-BIH team of the National Strategy for Gene- and Cell-Based Therapies cordially invite you to their joint workshop on GCT in Frankfurt/Main. Join ForTra and the SPARK-BIH team of the National Strategy for Gene- and Cell-Based Therapies for an inspiring, forward-looking workshop on Gene and Cell therapy (GCT) – one of the most dynamic fields shaping t
bottom of page